Peptides and Muscle Growth: What the Research Actually Reports

Searches about peptides and muscle growth usually assume that a body of human trials exists showing peptides increase muscle in healthy, training populations. The published literature is organised differently. Most peer-reviewed human data on peptides and skeletal muscle comes from metabolic medicine, where investigators tracked lean body mass while participants lost weight on peptide-based drugs. Additional evidence sits in preclinical models, mechanistic cell and animal studies, narrative reviews written for clinicians, and isolated case reports. This page summarises what those papers reported and does not describe how any compound should be used.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, supplement, or research compound.

How Peptides Are Described to Act on Muscle in the Literature

A peptide is a short chain of amino acids. Because that definition is structural rather than functional, the compounds grouped under the label act through entirely different receptors and pathways. The published work relevant to skeletal muscle clusters into a few mechanistic families.

Incretin receptor signalling and body composition

The largest human dataset involves glucagon-like peptide-1 (GLP-1) based therapies. A 2024 review in Diabetes, Obesity & Metabolism examined changes in lean body mass with GLP-1-based therapies and discussed mitigation strategies (PMID 38937282). A 2025 review in Current Opinion in Endocrinology, Diabetes, and Obesity likewise summarised the effect of GLP-1 receptor agonists on body composition (PMID 41076575). Importantly, this literature concerns lean mass retention during weight reduction, not muscle gain.

Activin and myostatin pathway modulation

A second mechanistic family targets negative regulators of muscle mass. In a 2024 Molecular Metabolism study, researchers reported that antibody blockade of activin type II receptors preserved skeletal muscle mass and enhanced fat loss during GLP-1 receptor agonism (PMID 38218536). That work is preclinical and was framed as a combination strategy rather than a standalone muscle-building intervention.

Growth hormone axis secretagogues

Compounds that stimulate growth hormone release are frequently discussed alongside peptides in fitness contexts, even when they are not peptides themselves. MK-677 (ibutamoren) is an orally active secretagogue; a 2025 BMJ Case Reports article described hepatotoxicity induced by MK-677 (PMID 40675653). A 2026 primer in The American Journal of Sports Medicine reviewed injectable peptide therapy for orthopaedic and sports medicine physicians, situating these agents within clinical practice and oversight questions (PMID 41476424).

Amino acids as substrate rather than signal

Free amino acids and short peptide blends are sometimes marketed interchangeably with peptide drugs, although the mechanism differs. A 2025 Nutrients paper discussed the role of amino acid supplementation in optimizing body composition during weight loss (PMID 40573110), treating amino acids as nutritional substrate for protein synthesis rather than as receptor-targeted drugs.

Upstream molecular regulation

Some mechanistic research examines the transcriptional and epigenetic machinery behind muscle cell growth. A 2024 Cell Death & Disease study investigated the functional role of the m6A demethylase ALKBH5 in cardiomyocyte hypertrophy (PMID 39294131). That work concerns cardiac muscle, not skeletal muscle hypertrophy in exercising humans, and illustrates how far upstream much "muscle growth" biology sits from anything tested in people.

What Studies Report About Peptides and Lean Mass

The most consistent theme in the human literature is measurement of lean mass during pharmacologically driven weight loss. A 2024 systematic review in Expert Opinion on Pharmacotherapy drew on clinical trials to examine the effect of semaglutide on lean mass (PMID 38629387). A 2026 article in Acta Diabetologica addressed muscle loss and GLP-1 receptor agonist use as a clinical concern (PMID 41201615).

Interpretation of those numbers is contested. A 2024 paper in the Journal of the Endocrine Society argued that fundamental body composition principles provide context for fat-free and skeletal muscle loss observed with GLP-1 receptor agonist treatments (PMID 39372917), noting that fat-free mass changes accompany any substantial weight reduction and that scanning methods do not measure contractile tissue directly. A 2025 review in Current Nutrition Reports considered the impact of GLP-1 receptor agonist therapy in patients at high risk for sarcopenia (PMID 40289060), which frames the question as protecting existing muscle in vulnerable groups.

Read together, this body of work describes peptide-based drugs as agents whose muscle-related literature is about loss and preservation, not accretion. None of the cited papers evaluated whether these compounds add muscle to healthy trained individuals.

Compound Classes and What the Cited Literature Covered

Why Gym and Bodybuilding Discussion Diverges From the Literature

In online fitness communities, "peptides" functions as an umbrella term for anything injectable and short-chain, and the claims attached to it — hypertrophy, recovery, joint repair, fat loss — are usually drawn from anecdote, vendor marketing, or extrapolation from unrelated animal work. Forum threads and social posts are not indexed research, carry no protocol registration, no blinding, no measured product identity, and no adverse-event capture. The cited literature above does not test those claims.

Three gaps explain most of the mismatch:

• Population mismatch. Human peptide data on muscle comes from people with obesity or metabolic disease losing weight, not resistance-trained individuals in energy surplus, which is the setting the reviews above described (PMID 38937282).
• Outcome mismatch. Trials measured lean or fat-free mass by body composition scanning, and a body composition analysis noted the interpretive limits of those measures (PMID 39372917).
• Evidence tier mismatch. Findings on muscle-preserving pathways came from preclinical antibody work rather than human hypertrophy trials (PMID 38218536).

Discussion of peptides "for men" follows the same pattern: the cited papers did not define a male-specific peptide category, and the sarcopenia-focused review framed muscle preservation around clinical risk rather than sex or training status (PMID 40289060).

Is There a "Best" Peptide for Bodybuilding in the Published Research?

The verified literature does not answer that question, because no head-to-head hypertrophy trial in trained humans exists among these papers. Comparative language would require studies that randomised trained participants to different peptides with matched training and nutrition and measured muscle size or strength. The available work instead compared lean mass outcomes within weight-loss pharmacotherapy (PMID 38629387), tested a combination strategy in animals (PMID 38218536), and reviewed clinical use patterns for physicians (PMID 41476424). Ranking claims circulating outside the literature are therefore unsupported by these sources.

Adverse Events and Safety Signals: What Studies Report

Safety reporting in this area is uneven. The single clearest signal among the cited papers is organ toxicity from a growth hormone secretagogue: a 2025 case report described hepatotoxicity induced by MK-677 (PMID 40675653). A case report describes one patient and cannot establish incidence, but it documents that harm has been reported with a compound widely discussed in fitness settings.

For GLP-1-based therapies, the muscle-related concern raised in the literature is loss of lean tissue rather than gain. Reviews addressed muscle loss with GLP-1 receptor agonist use (PMID 41201615) and considered risk in patients predisposed to sarcopenia (PMID 40289060), while mitigation approaches were discussed in a 2024 review of lean body mass change with these therapies (PMID 38937282). Nutritional strategies were reviewed separately, with a 2025 paper discussing amino acid supplementation during weight loss (PMID 40573110).

For research-grade peptides sold outside approved pharmaceutical channels, there is no comparable safety literature at all. Purity, identity, sterility, and contamination are not characterised in the cited papers, and the sports medicine primer addressed injectable peptide therapy as a clinical and oversight issue for physicians (PMID 41476424).

Regulatory and Research Status

Approved peptide medicines exist for defined indications such as type 2 diabetes and obesity, and those approvals do not extend to muscle building or athletic performance. Many other compounds discussed in fitness contexts are labelled research use only, meaning they are intended for laboratory work and are not authorised for human administration; some are handled through compounding pathways subject to separate rules. Anti-doping bodies also list many growth hormone secretagogues and related agents as prohibited substances in sport. Regulatory categories differ by jurisdiction and change over time.

What the Evidence Base Is Still Missing

1. Hypertrophy endpoints in healthy trained humans. None of the cited studies measured muscle cross-sectional area, fibre size, or strength gains in resistance-trained participants.
2. Long-term follow-up. The muscle-related GLP-1 literature was reviewed largely around weight-loss trial durations, and reviewers noted interpretation depends on body composition principles (PMID 39372917).
3. Translation of preclinical findings. Activin type II receptor blockade findings were reported in a preclinical setting and were not extended to trained human populations in that work (PMID 38218536).
4. Systematic harm surveillance. Outside approved drugs, adverse events appear as isolated reports such as the MK-677 hepatotoxicity case (PMID 40675653) rather than through structured monitoring.

Until trials with hypertrophy endpoints in trained humans exist, statements that peptides build muscle remain outside what the cited literature reported. Readers evaluating claims can check whether a source names a specific compound, a specific population, a measured outcome, and a published citation — and whether the paper studied muscle gain at all, or only muscle preservation during weight loss.

References

• Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies (Diabetes, Obesity & Metabolism, 2024)
• A systematic review of the effect of semaglutide on lean mass: insights from clinical trials (Expert Opinion on Pharmacotherapy, 2024)
• Muscle loss and GLP-1R agonists use (Acta Diabetologica, 2026)
• Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (Molecular Metabolism, 2024)
• Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments (Journal of the Endocrine Society, 2024)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Effect of GLP-1 receptor agonists on body composition (Current Opinion in Endocrinology, Diabetes, and Obesity, 2025)
• Hepatotoxicity induced by MK-677 (BMJ Case Reports, 2025)
• Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation (Nutrients, 2025)
• Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia (Current Nutrition Reports, 2025)
• The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy (Cell Death & Disease, 2024)